The annual incidence of diagnosed venous thromboembolism (VTE) is one to two events per 1000 of the general population. 1 Over half of these cases are deep vein thrombosis (DVT) and three-quarters of these are first episodes. The incidence of VTE is similar for men and women and presents less frequently in Asians than in Caucasians or Africans. It is uncommon in the under 20s, but after 40 years of age the incidence doubles with each decade of life. 2 Hereditary risk factors include the Factor V Leiden mutation, G20210A prothrombin gene mutation and deficiencies in protein C, protein S and antithrombin. Hereditary and/or acquired risk factors are hyperhomocysteinaemia and elevated levels of factors I, VIII and IX. Acquired risk factors include malignancy, hospitalization/immobility, surgery, venous trauma, oestrogen therapy, pregnancy and the presence of antiphospholipid antibodies. 2 On diagnosis, DVTs can be subdivided into idiopathic DVT (IDVT), that is, without a triggering factor and secondary DVT (SDVT).
The association between DVT and subsequent diagnosis of malignancy was made more than a century ago in 1865 by Armand Trousseau. 3 Unfortunately in 1866, he himself developed an unexplained DVT and subsequently, a year later, the diagnosis of gastric carcinoma was made. 4 The causes of thrombosis are a triad of stasis of blood, alteration in the composition of blood and changes in the vessel wall (Virchow's triad). 5 Cancer has a known association with thrombocytopenia. 6 Tumours produce thrombin, which aids tumour cell adhesion and tissue factor, which acts as a potent coagulant. 7 Increased levels of factor VIII and fibrinogen are also present. 8 These malignant mechanisms can affect all sides of Virchow's triad and thus significantly increase the risk of thrombosis formation in this vulnerable group of patients. Additionally, these patients may have risk factors unrelated to malignancy that contribute to increase their risk of incidence.
At present, clinically, we do not routinely investigate for malignancy in patients presenting with DVT. Many studies have been performed to see whether or not it would be beneficial to change this practice. It has been shown that there is an increased incidence (approximately four-to fivefold) of subsequent malignant diagnosis in patients presenting with IDVT (i.e. no other risk factors) in comparison with those with SDVT. [9] [10] [11] [12] [13] The risk for occult cancer is higher among elderly patients. 10, 11 Gender and localization of the DVT are not associated with a higher incidence of malignancy. 9 However, there are few, if any, reports of unsuspected malignancy diagnosed after an IDVT among Asian patients. 14 Reports suggest that a thorough clinical history, examination, routine laboratory blood tests and chest X-ray are adequate investigations to diagnose those at risk from an underlying occult malignancy. A high proportion of patients presenting with IDVT, caused by an unknown malignancy, had obvious clinical findings supporting their underlying diagnosis. 13 Evidence has suggested that certain cancers are associated with a higher incidence of DVT. These are malignancies of the pancreas, ovary, liver, brain, lymphoid tissue and bone marrow. 14 Despite this, it has been reported that abdominal ultrasound scanning is not beneficial as a compulsory part of a DVT protocol. More specialized blood tests, such as analysing D-dimer levels and tumour markers, have also been shown to have poor sensitivity, specificity and poor positive predictive value; although a negative result from both of these tests is a strong negative predictor for malignancy. 15, 16 Most abnormalities were identified using basic clinical techniques, as suggested above earlier and further imaging/investigation proved costly, not only through its own costs but also due to follow-up tests for false positive results. 12 Despite conclusive evidence of a strong link between idiopathic VTE and the risk of hidden cancer, results so far have been contradictory and have therefore made it difficult to define suitable recommendations on when to look for an underlying cancer. Screening all patients with DVT for cancer would not be cost-effective and routine diagnostic tests (including clinical examination and laboratory blood tests) are able to detect the majority of cancers if used properly. However, it seems a recognized fact that very few patients would benefit from earlier diagnosis because of other factors such as age, general health and tumour type that would make it difficult to alter the natural outcome of the disease.
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